Conversely, the use of therapeutics such as aspirin and platelet P2Y12 inhibitors has become standard of care in treating platelet hyperactivity associated with acute coronary syndromes and subsequent MACE. This evidence concerns the gene P2RY12 and acute coronary syndrome.